On February 3, 2026, Sagent Pharmaceuticals announced the FDA approval of its Abbreviated New Drug Application for generic doxorubicin hydrochloride liposome, addressing a high-value oncology market still dominated by a single brand competitor. This GRAS filing allows Sagent to enter the intravenous space, potentially pressuring manufacturers to face generic erosion as the bioequivalent alternative mitigates the financial stickiness of the branded alternative.